How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
|
|
- Jasper Powell
- 6 years ago
- Views:
Transcription
1 ACUTE MYELOID LEUKEMIA: NEWLY DISCOVERED GENES, SCREENS (FOR MINIMAL RESIDUAL DISEASE), AND THERAPEUTIC MEANS How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Jay P. Patel 1 and Ross L. Levine 1,2 1 Human Oncology and Pathogenesis Program, and 2 Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adults, and the majority of patients with AML die from relapsed disease. Although many studies over the past 4 decades have identified disease alleles in AML, recent genome-wide and candidate gene studies have identified additional recurrent somatic mutations in AML patients with biologic, clinical, and therapeutic importance. Herein we review our current understanding of the molecular pathogenesis of AML and discuss how mutational profiling can be used to refine prognostication in AML and to inform therapeutic approaches. We also review the current challenges in translating genomic studies to the clinical setting, which remains a significant challenge and an urgent priority. Introduction Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adult patients. Although most patients achieve complete remission with induction chemotherapy, the majority of patients relapse after achieving clinical remission. The use of consolidation therapy with high-dose cytarabine or stem cell transplantation improves outcomes in adult AML patients; however, despite the use of intensive consolidation strategies, outcomes for AML patients remain poor. Novel therapies are needed for patients with AML based on novel insights into AML pathogenesis. In addition, there is significant heterogeneity in outcome in AML; some patients are cured with the used of induction and consolidation chemotherapy alone, whereas others require allogeneic stem cell transplantation for curative intent or develop relapsed, refractory disease that is not amenable to current pharmacologic or immunologic approaches. Therefore, there is a pressing need to identify biomarkers that accurately predict outcome in AML so that patients are matched to the most appropriate therapies based on prognostic risk and therapeutic response. In the current clinical setting, a relatively small subset of genetic abnormalities are used to predict outcome and to direct therapy in AML. These include CBF translocations and translocations associated with acute promyelocytic leukemia, which predict for favorable outcome with induction/consolidation and for sensitivity to all-trans retinoic acid and arsenic trioxide, respectively. More recently, based on work by Schlenck et al and others in the field, it has been shown that mutational analysis of FLT3 in combination with NPM1 or CEBPA mutations can be used to predict outcome in normal karyotype AML and to identify patients who will benefit from allogeneic stem cell transplantation. 1 However, a large number of AML patients lack any of these abnormalities and there remains significant heterogeneity in clinical outcome within currently classified prognostic groups. These observations suggest there are additional biomarkers that can predict outcome in AML. Recent genetic studies have identified an increasing number of recurrent somatic mutations in AML patients, including mutations in TET2, 2,3 ASXL1, 4,5 IDH1 6 and IDH2, 7,8 DNMT3A, 9-11 and PHF6. 12 In addition, several of these newly identified genetic abnormalities have been shown to have prognostic importance in AML. Herein we review the prognostic relevance of novel AML disease alleles and discuss how genetic data can be used to inform outcome and therapy in AML. Identification of novel disease alleles in AML patients TET2 mutations In 2009, 2 groups of investigators mapped microdeletions and copy neutral loss of heterozygosity on chromosome 4q24 to identify recurrent somatic mutations in TET2 patients with myelodysplastic syndrome (MDS) and with myeloproliferative neoplasms. 2,13 Subsequent studies of large cohorts of patients with a spectrum of myeloid malignancies identified TET2 mutations in a spectrum of myeloid malignancies, including in 10% of AML patients. 3 TET2 is a member of the TET family of proteins. Recent biochemical studies have identified a novel epigenetic function for this class of enzymes, specifically the Fe(II) and alpha-ketoglutarate dependent conversion of 5-methylcytosine to 5-hydroxymethylcytosine hydroxymethylcytosine serves as an intermediate step to DNA demethylation, consistent with the TET family enzymes functioning to remove DNA methylation and with increased promoter methylation in mutant AML patients. 15 In addition, recent functional studies using murine models demonstrated that loss of Tet2 in the hematopoietic compartment results in increased self-renewal and in impaired hematopoietic differentiation in vivo ASXL1 mutations Analysis of array-comparative genomic hybridization based copy number data for somatic alterations in epigenetic modifiers led to the identification of somatic deletions and mutations in ASXL1 in MDS patients. 4 Similar to TET2, ASXL1 mutations are found in a spectrum of myeloid malignancies, including myeloproliferative neoplasms, MDS, AML, and, most commonly, chronic myelomonocytic leukemia. 4,20 ASXL1 mutations are relatively uncommon in younger patients with AML (occurring in 3%-5% of patients), 21 but the prevalence of ASXL1 mutations is increased in elderly patients with AML (occurring in approximately 16% of patients). 22 Given that the majority of ASXL1 mutations are somatic nonsense or frameshift mutations, it has been postulated that ASXL1 mutations result in loss of ASXL1 function; however, the precise mechanism of transformation remains elusive American Society of Hematology
2 IDH1 and IDH2 mutations IDH1 mutations were first identified in exome-sequencing studies of patients with malignant glioma, 24,25 and subsequent whole-genome sequencing efforts identified recurrent IDH1 mutations in AML. 6 Later candidate gene-sequencing studies identified IDH2 mutations in AML, 7,8 including leukemia-specific recurrent mutations at residue R140. Mutations in IDH1 and IDH2 occur in approximately 15%-30% of patients with AML, with an increased frequency of IDH mutations in older AML patients. IDH1 and IDH2 are enzymes critical in the Krebs cycle that normally convert isocitrate to alpha-ketoglutarate in a NADP - dependent manner. The presence of recurrent somatic mutations at highly conserved arginine residues in the active site of IDH1 and IDH2 led investigators to search for novel, neomorphic functions that contribute to malignant transformation. Metabolomic and enzyme-profiling studies demonstrated that mutant IDH proteins acquire a neomorphic enzymatic activity that converts alphaketoglutarate to 2 hydroxyglutarate (2-HG) HG can be detected in vast excess in the serum and BM of AML patients with IDH1/2 mutations, 8,27 suggesting that it may serve as a biomarker for this genetically defined subset of AML patients and as a measure of residual disease after AML therapy. However, the pleiotropic roles by which the IDH mutant mediated production of 2-HG contributes to leukemia pathogenesis has not been fully delineated. Based on mutual exclusivity between IDH1/2 and TET2 mutations in AML, it was demonstrated that IDH mutant mediated 2-HG production can inhibit the function of the alpha-ketoglutarate dependent TET enzymes and lead to hypermethylation in AML. 15 Expression of IDH mutants in hematopoietic cells causes increased expansion of hematopoietic stem cells and impaired hematopoietic differentiation, similar to what is seen with loss of Tet2 28 and consistent with a convergent mechanism of leukemic transformation. PHF6 mutations Mutations in PHF6 were first identified in T-cell acute lymphoblastic leukemia using next-generation sequencing of the X chromosome. 29 The majority of mutations are nonsense or frameshift alleles, again consistent with a loss-of-function role for PHF6 in leukemogenesis. Subsequent candidate gene sequencing of PHF6 in AML revealed that approximately 3% of patients harbored PHF6 mutations. 12 PHF6 is a plant homeodomain finger containing protein, an important highly conserved domain important in recognizing protein-dna interactions and histone modifications. In T-cell acute lymphoblastic leukemia, loss of PHF6 is associated with expression of the oncogenes TLX and TLX3, and the genetic data are consistent with PHF6 functioning as a X-linked tumor suppressor. The role of PHF6 mutations in AML pathogenesis has yet to be elucidated. DNMT3A mutations The first report of somatic mutations in DNMT3A came from studies using targeted next-generation sequencing, which led to the identification of recurrent mutations at the highly conserved R882 residue. 9 Later that year, 2 studies using whole-genome and whole-exome sequencing identified DNMT3A mutations throughout the entire open reading frame at a high frequency in AML. 10,11 In these 2 studies and in later reports, DNMT3A mutations have been found in more than 20% of adult AML patients, making it the second most common somatic mutation, after FLT3 mutations, in de novo AML identified to date. DNMT3A functions as a de novo methyltransferase that methylates cytosines in CpG dinucleotides. However, the specific role of DNMT3A mutations in altering epigenetic patterning and in AML pathogenesis has not been delineated conclusively. The genetic data are in part consistent with a tumor-suppressor role for DNMT3A in AML, because many patients present with frameshift or nonsense mutations. However, approximately 50% of AML patients present with mutations at codon R882 while retaining the second, wild-type DNMT3A allele, which is consistent with potential acquisition of a neomorphic function for DNMT3A point mutations. Initial studies of DNA methylation using array-based platforms have not identified significant alterations in global methylation levels in DNMT3A mutant AML patients, 10 suggesting that the effects of DNMT3A mutations on DNA methylation are likely site and context specific. More recent studies of Dnmt3a-deficient mice have revealed that loss of Dnmt3A in hematopoietic stem cells results in impaired cell differentiation, increased self-renewal with serial transplantation, and expansion of the hematopoietic stem cell pool. 30 Prognostic relevance of newly identified genes Although a series of elegant studies over the past decade have identified a large set of mutations and overexpressed genes with prognostic relevance in AML, 31 in the clinical setting, most AML centers use cytogenetic abnormalities and a relatively small set of gene-based tests to assign risk in AML and to determine postremission therapy. The relative paucity of clinically used biomarkers is due to several factors. First, most biomarker studies focus on a specific genetic lesion and its prognostic relevance without considering the complete set of known mutations in parallel to determine, which mutations predict outcome independently in AML. Second, most studies consider each mutant allele as a distinct variable without considering complex genotypes in which the presence/ absence of multiple disease alleles has different effects on outcome than individual mutations by themselves. Third, many studies have focused on mutational hotspots or have used less sensitive techniques to identify loss-of-function mutations in large tumor suppressors. Finally and most importantly, until recently, most studies of AML were relatively small in size and/or were not derived from clinical trial cohorts in which the effects of treatment on outcome can be controlled and investigated. Given the increasing number of genetic abnormalities that have been identified in AML patients, it has become important to determine the prognostic relevance of all known recurrent genetic abnormalities in a uniformly treated AML patient cohort. The largest such study to date used high-throughput resequencing 21 of TET2, ASXL1, DNMT3A, PHF6, WT1, TP53, RUNX1, EZH2 PTEN, FLT3, NPM1, CEBPA, HRAS, KRAS, NRAS, KIT, IDH1, and IDH2 in 502 patients from the Eastern Cooperative Oncology Group (ECOG) E1900 trial. 32 This trial evaluated the use of anthracycline dose intensification during induction therapy. A total of 657 patients between the ages of 17 and 60 years with de novo AML were randomized to receive standard induction with 45 mg/m 2 of daunorubicin plus cytarabine or to receive dose-intensive induction with 90 mg/m 2 of daunorubicin plus cytarabine. This large, homogeneously treated patient cohort allowed for extensive mutational profiling from diagnostic samples and correlation with outcome, including disease-free and overall survival and response to induction therapy. Integrated genetic analysis revealed 3 recently identified genes with prognostic importance in the total cohort of AML patients. Specifically, IDH2 R140 mutations, but not IDH2 R172 mutations or IDH1 mutations, were associated with improved overall survival in the entire E1900 cohort. These data suggest that there are important Hematology
3 qualitative and/or quantitative differences in the various IDH1/2 mutations in AML, and that these allele-specific differences in biology have relevance to outcome in AML. In addition, mutations in ASXL1 and PHF6 were associated with adverse overall survival in AML, suggesting that these relatively rare AML disease alleles mark a subset of patients with adverse outcome and that biologic studies are needed to determine how these mutations contribute to leukemogenesis. Although the identification of single gene mutations with impact on outcome is of clinical and biologic importance, the main goal of mutational studies should be to inform and improve prognostic algorithms in AML. Given the established importance of the 3 broad cytogenetic risk categories in AML, it is therefore important to determine whether mutational status for specific mutations or for combinations of mutations affect outcome in different cytogenetic risk categories. However, to date, most studies have failed to identify robust predictors that modify outcome in patients with favorable or unfavorable cytogenetic risk, suggesting that chromosomal lesions remain the best predictor of outcome for the 40% of AML patients with favorable or unfavorable karyotypic risk. In contrast, mutational studies have been able to increasingly refine prognosis in patients with intermediate-risk and/or normal karyotype AML. Previous studies have suggested that mutational analysis of CEBPA, NPM1, and FLT3-ITD can be used to risk-stratify intermediate-risk AML patients. 1 However, more extensive mutational analysis better discriminates intermediate-risk AML patients into robust, clinically relevant risk groups (Figure 1). 21 In the subset of patients with FLT3-ITD negative intermediate-risk AML, there are 3 distinct risk groups that are based on mutational status and have vastly different outcomes. FLT3-ITD negative, NPM1/IDH mutant patients have outcomes that are better than patients with inv(16)- or t(8:21)-positive AML, suggesting that this represents a favorable-risk AML subset defined by a specific mutational genotype. In contrast, FLT3-ITD negative NPM1 mutant patients without concurrent IDH mutations have a much less favorable outcome. Most importantly, the presence of poor-risk mutations, specifically TET2, ASXL1, PHF6, and/or MLL-PTD is associated with very adverse overall survival for FLT3-ITD wild-type, intermediate-risk patients. These data suggest that NPM1 mutational status alone does not define a favorable subset of intermediate-risk AML, and that the presence or absence of additional disease alleles defines relapse risk in FLT3-ITD wild-type, intermediate-risk AML. In addition, mutational studies allow for improved prognostication in intermediate-risk patients who are FLT3-ITD positive. Among FLT3-ITD mutant patients, concurrent mutations in TET2, DNMT3A, MLL-PTD, or trisomy (8) were associated with very poor outcome. This is a relatively large subset of patients and approximately 47% of the total intermediate-risk FLT3-ITD patient subset fall into this very-high-risk subset. Therefore, the category of intermediaterisk FLT3-ITD patients with 1 of these 4 mutations forms a new subset of FLT3-ITD, intermediate-risk AML patients and this may have important implications for treatment decisions. In addition, patients who have the FLT3-ITD mutation without the addition of any of the 4 genetic abnormalities actually have a similar outcome to FLT3-ITD/CEBPa double-mutant patients. These data suggest that mutational profiling can be used to improve prognostication in AML, such that intermediate-risk patients can be reclassified as having favorable, intermediate, or poor risk based on the mutational status of 9 genes (Figure 2). This has important clinical implications, because patients with mutationally defined favorable risk have a better outcome with standard induction and consolidation than even patients with core binding factor positive AML. In contrast, patients with mutationally defined adverse-risk AML have an outcome similar to patients with adverse karyotypic risk, and standard therapies are not sufficient to offer curative intent to the majority of these patients. We contend that future clinical trials should aim to identify genetically defined high-risk patients to offer these patients novel therapies early in their disease course, including novel therapeutic approaches to induction, consolidation, and maintenance therapy in an effort to reduce relapse and increase cure. Although these studies that suggest mutational profiling offers significant added value to prognostication in AML, validation of these findings in other large, homogeneously treated patient cohorts is of utmost clinical importance. The findings from the E1900 trial were validated in an independent set of patients from the same cohort, but additional studies are needed to validate these results and extend them as additional disease alleles are identified in AML patients. In some cases, the results from different studies of specific genetic alterations has been inconsistent, including in the case of mutations in IDH1 and/or IDH However, data from the Medical Research Council trials in younger adults treated with aggressive therapy (induction followed by allogeneic or autologous transplantation) described favorable outcome with IDH2 R140 mutations or with double NPM1/IDH2 mutations, 36 suggesting that cohort size, age, and treatment approach have significant effects on prognostication in AML. Therefore, subsequent biomarker efforts should determine whether different mutational genotypes predict outcome in large cohorts of younger and older adults treated with different AML therapies or if similar prognostic schemas can be used in different clinical contexts. Anthracycline dose intensification for induction therapy in AML The most widely used induction regimen for AML has remained the same for more than 30 years: 3 daily doses of daunorubicin (or its equivalent, anthracycline) at 45 mg/m 2 and 7 days of cytarabine. As noted earlier, the ECOG E1900 trial evaluated the use of anthracycline dose intensification during induction therapy. A total of 657 patients between the ages of 17 and 60 years with de novo AML were randomized to receive either the standard 45 mg/m 2 dose of daunorubicin or a higher dose of 90 mg/m 2. The higher-dose cohort achieved a higher rate of complete remission and an increase in overall survival. The benefit of high-dose daunorubicin was restricted to those less than 50 years age of age and to those AML patients with cytogenetically defined favorable or intermediate risk. A subsequent study investigating high-dose versus low-dose daunorubicin in AML patients younger than 60 years of age reported findings similar to the ECOG E1900 trial. 37 A similar study in patients older than 60 years 38 observed an increased rate of complete remission in the higher-dose cohort (64% vs 54%). However, prolonged overall survival was only seen in patients under the age of 65 years and those with core-binding factor positive leukemia. Unfortunately, these previous studies did not include prospective mutational profiling to identify biomarkers that could be used to delineate subsets of patients who would most benefit from intensified chemotherapy. This is particularly important given the heterogeneity in outcome in these clinical trials. A subsequent, post hoc analysis of mutational status, induction therapy, and outcome in the E1900 cohort revealed that high-dose daunorubicin improved outcomes markedly for patients with DNMT3A mutations. 21 Patients 30 American Society of Hematology
4 Figure 1. Mutational complexity and prognosis in intermediate-risk AML. (A-B) Circos plots of AML patients with cytogenetically defined intermediate-risk disease with intermediate mutational risk (A) or unfavorable mutational risk (B). (C) Survival curves for FLT3-ITD positive and negative intermediate-risk disease (used with permission from Patel et al 21 ). with mutant DNMT3A receiving high-dose daunorubicin had similar outcome to DNMT3A wild-type patients receiving high-dose or standard-dose daunorubicin. Patients with MLL fusions or with NPM1 mutations also had improved overall survival when treated with high-dose daunorubicin (Figure 3). Interestingly, MLL fusions were mutually exclusive with DNMT3A and NPM1 mutations, suggesting a potential shared biologic mechanism explaining sensitivity to daunorubicin. In total, patients with NPM1 or DNMT3A mutations or MLL translocations comprised 44.2% of the E1900 cohort; the 3-year overall survival for this group as a whole improved from 25% to 44% when the patients were treated with high-dose daunorubicin induction chemotherapy. A recent study suggested that patients with exon 23 mutations in DNMT3A had improved overall survival when treated with 12 mg/m 2 of idarubicin (nearly equivalent to high-dose daunorubicin) versus daunorubicin, 39 but these findings need to be further validated in a prospective clinical trial. These results suggest that mutational studies can be used to identify patients who benefit from dose-intense induction chemotherapy and provide an example of how molecular profiling can be used to decipher clinical heterogeneity in large, phase 3 AML trials. Hematology
5 The evolution of relapsed AML Despite an initial response to induction/consolidation therapy, most AML patients relapse with disease that is broadly resistant to chemotherapy. A recent study provided the first large-scale insight into the genetics of relapsed AML by performing whole-genome sequencing of 8 AML patients with relapsed AML. 42 In each case, the AML genome at diagnosis and at relapse was sequenced and compared with genome sequencing of matched normal tissue. Instead of restricting themselves to somatic events in coding Figure 2. Revised risk stratification of patients with AML on the basis of integrated genetic analysis. Prognostic algorithm and survival curves with integrated mutational profiling are shown (used with permission from Patel et al 21 ). Prognostic effect of novel genes in pediatric AML Very few studies have assessed the prognostic value of recently identified genes in pediatric AML. A study of 460 pediatric patients with AML identified IDH1 and IDH2 mutations in 4% of this large cohort 40 and IDH mutations were associated with improved overall survival in univariate analysis. Studies of the frequency of IDH1/2, TET2, and DNMT3A have shown that these mutations are rare compared with their frequency in adult AML, 41 occurring in less than 5% of patients. For example, DNMT3A mutations have not been reported in pediatric AML, whereas approximately 22% of adult AML patients harbor DNMT3A mutations. These data suggest that pediatric AML may have markedly different genetic and epigenetic features compared with adult AML and may need to be studied as a separate entity to improve prognostication and to inform the biology of pediatric AML. Figure 3. Molecular determinants of response to high-dose daunorubicin induction chemotherapy. Benefit of high-dose versus standard-dose daunorubicin in patients with NPM1/DNMT3A mutations or with MLL translocations compared with those wild-type for all 3 AML disease alleles is shown (used with permission from Patel et al 21 ). 32 American Society of Hematology
6 regions, the investigators validated all candidate somatic events in each tumor, allowing for a much greater number of mutations to be used to track the evolution from diagnosis to relapse. Two clear patterns emerged when the mutations found at diagnosis and at relapse were analyzed. In one model, a founding clone and multiple subclones clonally derived from this founding clone were extant at diagnosis. After chemotherapy, the residual cells from one of the minor subclones expanded to become the dominant clone at relapse. This clone also carried additional mutations that were only observed at relapse. Clonal progression from diagnosis to relapse of this nature was seen in 5 of the 8 patients in this study. In the other 3 patients in this study, the evolution from diagnosis to relapse was much simpler: the dominant clone at the time of diagnosis simply acquired more mutations at relapse. In all patients, there existed a founding clone that was not ablated by chemotherapy and was still persistent at relapse. Prospective identification of this clone at diagnosis would be of utmost clinical utility. The identification of mutations at diagnosis could serve as a tool for minimal residual disease measurement and allow for the deployment of therapies to eradicate residual clones after induction and consolidation therapy. Translating novel genetic findings to the clinic With the discovery of novel genes associated with AML pathogenesis continuing at a high speed, the challenge is to integrate this knowledge into the current clinical understanding of AML. Profiling each AML patient for clinically relevant and actionable lesions is the first step in this process. Although whole-genome and whole-exome sequencing have been critical technologies in cancer discovery efforts, their applicability today presents several challenges in the wider clinical setting. Although costs of sequencing are plummeting, the bioinformatics infrastructure and expertise needed to rapidly analyze sequencing data remain limiting in most settings. In addition, most of the mutational data in exome/genome studies represent passenger mutations and/or mutations without clinical or therapeutic relevance. Two recent proof-of-concept studies have demonstrated the feasibility of whole-genome sequencing in a specialized clinical setting. Welch et al 43 used whole-genome sequencing to identify a cryptic PML-RARA translocation in a patient with clinical features of M3-AML that was not detected using FISH for PML-RARA. Roychowdhury et al 44 performed whole-genome, whole-exome, and transcriptome sequencing on 2 patients with metastatic colorectal cancer and another with malignant melanoma. Even though groups at the cutting-edge of cancer genomics performed both of these studies, the studies still took 8 and 4 weeks to perform, respectively. Whole-genome sequencing will undoubtedly become part of the standard diagnostic evaluation within the next few years; however, the technology is currently not a feasible option for most AML patients at academic or nonacademic centers. In contrast, the use of capture technologies followed by nextgeneration sequencing may represent the best option for clinical use of molecular genetic information in the near term. In this process, the relevant genes are captured by either PCR reactions performed in microdroplets 45 or hybridized to oligonucleotide baits 46 and then sequenced using next-generation sequencing. As newer bench-top sequencers are developed and optimized, their faster sequencing turnaround (1-3 days) will allow for high-throughput, albeit focused, mutational studies in the clinical setting so that these data can be used to inform induction and postremission therapies in AML. Conclusion With the discovery of new, recurrently mutated genes in AML, the first step should be to interrogate the clinical relevance of the specific mutation in homogeneously treated clinical cohorts in the context of all other known AML disease alleles. This will allow the AML field to evaluate the relevance of specific biomarkers rapidly and to develop tests that allow for cost-effective, rapid molecular profiling in the clinical setting. Whereas functional studies of novel disease alleles will likely result in the identification of novel therapeutic targets and lead to a greater understanding of AML pathogenesis, the incorporation of novel biomarkers into the clinical setting is the most important short-term goal facing AML patients and clinicians today. Disclosures Conflict-of-interest disclosure: The authors declare no competing financial interests. Off-label drug use: None disclosed. Correspondence Ross L. Levine, MD, Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan- Kettering Cancer Center, 1275 York Ave, Box 20, New York, NY 10065; Phone: ; Fax: ; leviner@mskcc.org. References 1. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18): Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22): Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1): Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6): Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2): Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11): Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14): Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3): Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. Oncogene. 2010;29: Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25): Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4): Van Vlierberghe P, Patel J, Abdel-Wahab O, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011; 25(4): Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7): Hematology
7 14. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929): Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6): Ko M, Bandukwala HS, An J, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A. 2011;108(35): Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1): Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1): Li Z, Cai X, Cai C, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17): Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11): Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12): Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26): Abdel-Wahab O, Adli M, et al. ASXL1 mutations promote myeloid transformation through inhibition of PRC2-mediated gene repression [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118: Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5987): Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8): Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7300): Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2): Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6): Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(4): Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44(1): Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5): Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13): Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Blood. 2010;116(12): Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22): Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2010;28(23): Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2): Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14): Löwenberg B, Ossenkoppele GJ, van Putten W, et al. Highdose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13): LaRochelle O, Bertoli S, Vergez F, et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget. 2011;2(11): Damm F, Thol F, Hollink I, et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia. 2011; 25(11): Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children s Oncology Group. Pediatr Blood Cancer. 2011;57(2): Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382): Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011;305(15): Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3(111):111ra Tewhey R, Warner JB, Nakano M, et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol. 2009;27(11): Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol. 2009;27(2): American Society of Hematology
SUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationChanging AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike
More informationA bs tr ac t. n engl j med 366;12 nejm.org march 22,
The new england journal of medicine established in 112 march 22, 2012 vol. 66 no. 12 Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia Jay P. Patel, Mithat Gönen, Ph.D., Maria
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationJuan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1
Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1 Xin Hua Hospital, Shanghai, China 2 Oregon Health & Science University, Portland, OR, United States AML is a hematopoietic neoplasms characterized
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationRUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016
www.lls.org www.runx1.com RUNX1 and FPD/AML Translational Research The Leukemia and Lymphoma Society / Babich Family Foundation Partnership September 2016 Prepared by L. Greenberger, PhD Chief Scientific
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationCharacteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML AJH Courtney D. DiNardo, 1 * Farhad Ravandi, 1 Sam Agresta, 2 Marina Konopleva, 1 Koichi Takahashi, 1 Tapan Kadia,
More informationReview Article The Epigenetic Landscape of Acute Myeloid Leukemia
Advances in Hematology, Article ID 103175, 15 pages http://dx.doi.org/10.1155/2014/103175 Review Article The Epigenetic Landscape of Acute Myeloid Leukemia Emma Conway O Brien, Steven Prideaux, and Timothy
More informationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationFuture Targets for Acute Myeloid Leukemia
Future Targets for Acute Myeloid Leukemia E. Anders Kolb, M.D. Director, Nemours Center for Cancer and Blood Disorders Chair, Children s Oncology Group Myeloid Disease Committee Future Targets for Acute
More informationMolecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia
Hackl et al. Journal of Hematology & Oncology (2017) 10:51 DOI 10.1186/s13045-017-0416-0 REVIEW Open Access Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationRESEARCH ARTICLE. Firoz Ahmad 1, Rupali Mohota 1, Savita Sanap 1, Swarna Mandava 2, Bibhu Ranjan Das 1 * Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.3.1247 RESEARCH ARTICLE Molecular Evaluation of DNMT3A and IDH1/2 Gene Mutation: Frequency, Distribution Pattern and Associations with Additional Molecular Markers
More informationClassification and risk assessment in AML: integrating cytogenetics and molecular profiling
ACUTE MYELOID LEUKEMIA: HOW CAN WE IMPROVE UPON STANDARD THERAPY? Classification and risk assessment in AML: integrating cytogenetics and molecular profiling Matahi Moarii and Elli Papaemmanuil Department
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationSupplemental material Mutant DNMT3A: A Marker of Poor Prognosis in Acute Myeloid Leukemia Ana Flávia Tibúrcio Ribeiro, Marta Pratcorona, Claudia
Supplemental material Mutant DNMT3A: A Marker of Poor Prognosis in Acute Myeloid Leukemia Ana Flávia Tibúrcio Ribeiro, Marta Pratcorona, Claudia Erpelinck-Verschueren, Veronika Rockova, Mathijs Sanders,
More informationClonal Evolution of saml. Johnnie J. Orozco Hematology Fellows Conference May 11, 2012
Clonal Evolution of saml Johnnie J. Orozco Hematology Fellows Conference May 11, 2012 CML: *bcr-abl and imatinib Melanoma: *braf and vemurafenib CRC: *k-ras and cetuximab Esophageal/Gastric: *Her-2/neu
More informationAvailable online at
Annals of Clinical & Laboratory Science, vol. 45, no. 5, 2015 Available online at www.annclinlabsci.org Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases
More informationMutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics Marta Fernandez-Mercado 1, Bon Ham Yip 1, Andrea Pellagatti 1, Carwyn Davies 1, María José Larrayoz
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationGenomics of AML: Clinical Applications of Next-Generation Sequencing
ACUTE MYELOID LEUKEMIA IN THE AGE OF GENOMICS Genomics of AML: Clinical Applications of Next-Generation Sequencing John S. Welch 1 and Daniel C. Link 1 1 Division of Oncology, Department of Medicine, Washington
More informationREVIEW. Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis
DOI:10.22034/APJCP.2018.19.2.325 REVIEW Editorial Process: Submission:10/03/2017 Acceptance:12/16/2017 Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis Mahdi Jalili 1,2, Marjan Yaghmaie 1, Mohammad
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationMicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A
MicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A Heba Alkhatabi, PhD Assistant Professor Department of Medical Laboratory Collage of Applied Medical science King Abdul Aziz
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationMyelodysplastic syndrome is a highly heterogeneous hematopoietic
SHORT COMMUNICATION Clinical Characteristics and Prognosis of 48 Patients with Mutations in Myelodysplastic Syndrome Yulu Tian #, Ruijuan Zhang #, Linhua Yang* Yang L. Clinical Characteristics and Prognosis
More informationAML Genomics 11/27/17. Normal neutrophil maturation. Acute Myeloid Leukemia (AML) = block in differentiation. Myelomonocy9c FAB M5
AML Genomics 1 Normal neutrophil maturation Acute Myeloid Leukemia (AML) = block in differentiation AML with minimal differen9a9on FAB M1 Promyelocy9c leukemia FAB M3 Myelomonocy9c FAB M5 2 1 Principle
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationMolecularly targeted therapies for acute myeloid leukemia
Molecularly targeted therapies for acute myeloid leukemia Eytan M. Stein 1 TREATMENT OF ACUTE MYELOID LEUKEMIA:MOVING BEYOND 3 7 1 Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationSupplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
More information«Adverse Prognosis» Acute Myeloid Leukemia
23. Fortbildungskurs Lausanne, 11.11.2017 «Adverse Prognosis» Acute Myeloid Leukemia Markus G. Manz Zentrum für Hämatologie und Onkologie UniversitätsSpital Zürich Content AML Update on current definition
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationDNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia
Lu et al. Cancer Cell International 2013, 13:1 PRIMARY RESEARCH Open Access DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia Quanyi Lu 1*, Yamei Chen 1, Hang Wang
More informationTherapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328
Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationTherapeutic and Prognostic Role of Epigenetic Abnormalities in MDS. Stephen D. Nimer, MD Sylvester Comprehensive Cancer Center December 5, 2014
Therapeutic and Prognostic Role of Epigenetic Abnormalities in MDS Stephen D. Nimer, MD Sylvester Comprehensive Cancer Center December 5, 2014 DISCLOSURE I have no relevant financial relationships to disclose.
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationReview Article Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy
Hindawi Publishing Corporation Advances in Hematology Volume 2012, Article ID 469592, 12 pages doi:10.1155/2012/469592 Review Article Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationNews Release. Title Integrated molecular profiling of juvenile myelomonocytic leukemia
News Release Title Integrated molecular profiling of juvenile myelomonocytic leukemia Key Points We identified ALK/ROS1 tyrosine kinase fusions (DCTN1-ALK, RANBP2-ALK, and TBL1XR1-ROS1) in patients with
More informationCytogenetics and FLT3 ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
https://doi.org/10.1186/s40164-019-0127-z Experimental Hematology & Oncology RESEARCH Open Access Cytogenetics and FLT3 ITD mutation predict clinical outcomes in non transplant patients with acute myeloid
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationGenetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies
Genetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies Raajit Rampal, MD, PhD Assistant Attending Physician Leukemia
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationMolecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Published Ahead of Print on December 19, 2014, as doi:10.3324/haematol.2014.117267. Copyright 2014 Ferrata Storti Foundation. Cytogenetic heterogeneity negatively impacts outcomes in patients with acute
More informationMutational Impact on Diagnostic and Prognostic Evaluation of MDS
Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Papaemmanuil Lab, Computational Oncology, MSKCC MDS Foundation ASH 2018 Symposium Disclosure Research funds provided by
More informationFerrata Storti Foundation
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype Somatic mutations in JAK2, CALR and MPL are found in the majority of myeloproliferative
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationCan we classify cancer using cell signaling?
Can we classify cancer using cell signaling? Central hypotheses (big ideas) Alterations to signaling genes would cause leukemic cells to react in an inappropriate or sensitized manner to environmental
More informationWHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationA pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH
A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationThe role of mutations in epigenetic regulators in myeloid malignancies
Brittany A. Woods Ross L. Levine The role of mutations in epigenetic regulators in myeloid malignancies Authors addresses Brittany A. Woods 1,2, Ross L. Levine 1,2,3 1 Louis V. Gerstner Sloan Kettering
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More information